Психические расстройства в общей медицине. №1 2015

Паническое расстройство: опыт использования эсциталопрама

Е.В.Колюцкая

ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2

Стр. 47-51

2908 просмотров

Опубликовано: 27 августа 2015

Аннотация / Abstract

Паническое расстройство (ПР) принадлежит к числу наиболее распространенных форм пограничной психической патологии. Распространенность ПР на протяжении жизни варьирует от 1,6 до 2,2%. В настоящее время большинство препаратов, рекомендованных к использованию в терапии ПР, входят в группу СИОЗС, где особое место занимает эсциталопрам. Результаты проведенного исследования позволили установить, что эсциталопрам обладает высокой активностью по отношению к основным проявлениям ПР. В ходе исследования подтверждено, что препарат оказывает значимое влияние на интенсивность основных психопатологических проявлений данного типа, включая развернутые и ограниченные спонтанные и ситуационные панические приступы. Ключевые слова: паническое расстройство, эсциталопрам, психосоматика. kolutskaya@gmail.com Для цитирования: Колюцкая Е.В. Паническое расстройство: опыт использования эсциталопрама. Психические расстройства в общей медицине. 2015; 1: 47–51. Panic disorder: experience with escitalopram E.V.Kolyutskaya I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2. Panic disorder (PR) is one of the most common forms of borderline mental pathology. Prevalence PR lifetime varies from 1.6 to 2.2%. Currently, most of the drugs, the recommended for use in the treatment PR, part of the group of SSRIs, which occupies a special place escitalopram. Results of the study revealed that escitalopram has a high activity against the major manifestations of the PR. The study confirmed that the drug has a significant influence on the intensity of the main psychopathological manifestations of this type, including deployed and limited spontaneous and situational panic attacks. Key words: panic disorder, escitalopram, psycosomatics. kolutskaya@gmail.com For citation: Kolyutskaya E.V. Panic disorder: experience with escitalopram....

Материал для специалистов

Полный текст статьи доступен только зарегистрированным пользователям.

Вход / Регистрация

1. Колюцкая Е.В., Стась С.Ю. Эсциталопрам в терапии панического расстройства. Психиатр. и психофармакотер. 2006; 1: 20–2. / Koliutskaia E.V., Stas' S.Iu. Estsitalopram v terapii panicheskogo rasstroistva. Psikhiatr. i psikhofarmakoter. 2006; 1: 20–2.
2. American Psychiatric Association. Practice guidelines for the treatment of patients with panic disorder. Am J Psychiatry 1998; 155: 1–34.
3. Asnis GM, Hameedi FA, Goddard AW et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res 2001; 103: 1–14.
4. Ballenger JC, Wheadon DE, Steiner M et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155: 36–42.
5. Bandelow B, Zohar J, Hollander E et al. Task forse on treatment guidelines for anxiety. World J Biolog Psychiatry 2008; 9 (4): 248–312.
6. Burke WJ, Gergel I, Bose A. Fixed dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331–6.
7. Davidson J, Bose A, Su G. Escitalopram in the treatment of generalized anxiety disorder. Abstr. Int J Neuropsychopharmacol 2002; 5: 214.
8. Goddard AW, Charney DS. SSRIs in the treatment of panic disorder. Depress Anxiety 1998; 8 (Suppl. 1): 114–20.
9. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: Pooled analysis of placebo-controlled trials. CNS Spectrums 2002; 7: 40–4.
10. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: Role of human cyto-chromes P450. J Clin Psychiatry 1998; 59 (Suppl. 15): 19–27.
11. Hyttel J, Bogeso KP, Perregaard J et al. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992; 88: 157–60.
12. Kasper S, Loft H, Smith JR. Escitalopram is efficacious and well tolerated in the treatment of social anxiety disorder. Int J Neuropsychopharmacol 2002; 5: 131.
13. Kasper S, Resinger E. Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol 2001; 11: 307–21.
14. Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95: 145–52.
15. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95: 153–60.
16. Leinonen E, Lepola U, Koponen H et al. Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 2000; 25: 25–32.
17. Lepola UM, Wade AG, Leinonen EV et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998; 59: 528–34.
18. Lesser IM, Rubin RT, Pecknold JC et al. Secondary depression in panic disorder and agoraphobia. Pt. 1: Frequency, severity, and response to treatment. Arch Gen Psychiatry 1988; 45: 437–43.
19. Londborg PD, Wolkow R, Smith WT et al. Sertraline in the treatment of panic disorder: A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 1998; 173: 54–60.
20. Lydiard RB. Effects of escitalopram on anxiety symptoms in depression. World J Biol Psychiatry 2001; 2: 1.
21. Michelson D, Allgulander C, Dantendorfer K et al. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: Stahl et al. randomised, placebo-controlled trial. Br J Psychiatry 2001; 179: 514–8.
22. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: A placebo-controlled trial. J Clin Psychopharmacol 1992; 12: 251–61.
23. Mountjoy CQ, Roth M, Garside RF et al. A clinical trial of phenelzine in anxiety depressive and phobic neuroses. Br J Psychiatry 1977; 131: 486–92.
24. Owens M, Rosenbaum J. Escitalopram: A second-generation SSRI. CNS Spectrums 2002; 7: 34–39.
25. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50: 345–50.
26. Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 1998; 155: 1189–95.
27. Pollack MH, Marzol PC. Panic: course, complications and treatment of panic disorder. J Psychopharmacol 2000; 14: 25–30.
28. Pollack MH, Otto MW, Worthington JJ et al. Sertraline in the treatment of panic disorder: A flexible-dose multicenter trial. Arch Gen Psychiatry 1998; 55: 1010–6.
29. Roy-Byrne P, Wingerson D, Cowley D et al. Psychopharmacologic treatment of panic, generalized anxiety disorder, and social phobia. Psychiatr Clin North Am 1993; 16: 719–35.
30. Rosenthal MH, Li D. Efficacy and tolerability of escitalopram in patients intolerant of other SSRIs. Poster presented at: 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum. Montreal, Canada 2002.
31. Stahl SM, van Gergel I, Dayong L. Escitalopram in the treatment of panic disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003; 64: 1322–7.
32. Stahl SM. Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents. J Clin Psychiatry 2002; 63: 854–5.
33. Stahl SM. Mirror, mirror on the wall, which enantiomer is fairest of them all? J Clin Psychiatry 2002; 63: 656–7.
34. Starcevic V. Anxiety states: A review of conceptual and treatment issues. Curr Opin Psychiatry 2006; 19 (1): 79–83.
35. Tyrer P, Candy J, Kelly D. Phenelzine in phobic anxiety: A controlled trial. Psychol Med 1973; 3: 120–4.
36. Wade AG, Lepola U, Koponen HJ et al. The effect of citalopram in panic disorder. Br J Psychiatry 1997; 170: 549–53.
37. Wade A, Lemming OM, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95–102.
38. Zohar J, Westenberg HG. Anxiety disorders: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403: 39–49.

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

Паническое расстройство: опыт использования эсциталопрама

Материал для специалистов

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

Паническое расстройство: опыт использования эсциталопрама

Материал для специалистов

Con-Med Passport